Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$3.95 - $5.41 $519,626 - $711,690
-131,551 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$4.52 - $7.8 $29,379 - $50,700
-6,500 Reduced 4.71%
131,551 $696,000
Q4 2020

Feb 11, 2021

BUY
$4.37 - $9.46 $603,282 - $1.31 Million
138,051 New
138,051 $973,000

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Hite Hedge Asset Management LLC Portfolio

Follow Hite Hedge Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hite Hedge Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hite Hedge Asset Management LLC with notifications on news.